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1  | INTRODUC TION
The	 objectives	 of	 Group	 4	 of	 the	 6th	 ITI	 Consensus	 Conference	
were	to	provide	statements	and	recommendations	for	clinicians	and	





to	 the	 manuscripts.	 The	 working	 group	 formed	 consensus	 state‐
ments	 and	 clinical	 recommendations	 which	 were	 then	 presented	
and	accepted	following	further	discussion	and	modifications	when	
required	by	the	plenary.	Recommendations	for	future	research	were	
also	prepared	by	 the	working	group.	The	 four	 systematic	 reviews	
are	listed	below.
The	 Diagnosis	 of	 Peri‐implantitis:	 A	 systematic	 review	 on	 the	








Effect	 of	 advanced	 age	 and/or	 systemic	 medical	 conditions	 on	
	dental	 implant	 survival:	 A	 systematic	 review	 and	meta‐analysis	
(Schimmel,	Srinivasan,	McKenna,	Müller,	2018).
2  | THE DIAGNOSIS OF PERI‐
IMPL ANTITIS:  THE PREDIC TIVE VALUE OF 
BLEEDING ON PROBING
2.1 | Preamble





implantitis,	 BOP	 and/or	 suppuration	 (SUP)	 after	 at	 least	 1	year	 of	
functional	 loading	 were	 selected.	 Meta‐analyses	 were	 conducted	
to	combine	 the	proportions	of	peri‐implantitis	 among	BOP	and/or	
SUP‐positive	 subjects	 and	 implants	 across	 studies	 up	 to	 18	years.	
Materials and methods:	Four	systematic	reviews	formed	the	basis	for	discussion	in	




Results:	 Bleeding	 on	 probing	 (BOP)	 alone	 is	 insufficient	 for	 the	 diagnosis	 of	 peri‐
implantitis.	 The	 positive	 predictive	 value	 of	 BOP	 alone	 for	 the	 diagnosis	 of	 peri‐
implantitis	varies	and	 is	dependent	on	the	prevalence	of	peri‐implantitis	within	 the	
population.	 For	 patients	with	 implants	 in	 augmented	 sites,	 the	 prevalence	 of	 peri‐








is	 low.	 Peri‐implantitis	 treatment	 should	 be	 followed	 by	 individualized	 supportive	
care.	 Implant	 therapy	 for	 geriatric	 patients	 is	 not	 contraindicated;	 however,	
comorbidities	and	autonomy	should	be	considered.
K E Y W O R D S
augmentation,	complication,	geriatric,	implant	survival,	peri‐implantitis,	supportive	care,	
systemic	conditions
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Subgroups	 were	 created	 and	 compared	 to	 investigate	 potential	
sources	of	heterogeneity.


































2.3.2 | What does the predictive value of a 









2.4 | Recommendations for future research
•	 To	 investigate	 the	presence	of	BOP	as	 a	 risk	 factor	 for	 the	de‐
velopment	 of	 peri‐implantitis,	 specifically	 designed	 longitudinal	
studies	are	required.
•	 Biological	 conditions	of	human	BOP‐positive	and	negative	peri‐
implant	 tissues	 should	 be	 investigated,	 on	 a	 histological	 and	
molecular	 level,	 to	 better	 understand	 the	 underlying	 causes	 of	
bleeding	upon	probing.












3  | LONG ‐TERM BIOLOGIC AL 
COMPLIC ATIONS OF DENTAL IMPL ANTS 
PL ACED EITHER IN PRISTINE OR IN 
AUGMENTED SITES
3.1 | Preamble
Placement	 of	 dental	 implants	 in	 conjunction	 with	 augmentation	
procedures	 is	well	 documented	and	has	been	 shown	 to	yield	high	
predictability	in	terms	of	implant	survival	rates	and	volume	stability.	
However,	 a	 comparison	 between	 the	 long‐term	 prevalence	 of	
biological	 complications	 at	 implants	 placed	 in	 pristine	 sites	 (sites	
not	requiring	augmentation	prior	to	or	 in	conjunction	with	 implant	
placement)	versus	augmented	sites	is	lacking.




•	 In	 patients	with	 osseointegrated	 dental	 implants,	 are	 there	 dif‐
ferences	in	biological	complications	at	implants	placed	in	pristine	
versus	augmented	sites?
•	 In	 patients	with	 osseointegrated	 dental	 implants,	 are	 there	 dif‐
ferences	in	failure	rates	of	implants	placed	in	pristine	versus	aug‐
mented	sites?
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The	systematic	 review	 included	8	 investigations	 (1	RCT,	1	case–
control	study,	1	cross‐sectional	study,	5	case	series).	The	mean	number	









































There	 is	 some	 evidence	 that	 the	 long‐term	 prevalence	 of	 implant	
failure	(loss)	in	patients	with	implants	in	pristine	sites	and	augmented	
sites	is	low.
The	 weighted	mean	 prevalence	 of	 implant	 failure	 (loss)	 in	 pa‐
tients	with	implants	in	augmented	sites	was	3.6%	(95%	CI:	0%–8%)	





In	 patients	with	 a	 history	 of	 treated	periodontitis	 (moderate	 and	
severe)	receiving	implant	therapy	in	pristine	sites,	compliance	with	
regular	supportive	care	yields	lower	long‐term	implant	failure	(loss)	









3.3.1 | For the long‐term monitoring of biological 
complications, at what time points should implants 






3.3.2 | Do patients with implants in augmented sites 





3.4 | Recommendations for future research
•	 The	 influence	of	 factors	 including	defect	morphology,	 augmen‐
tation	 technique,	 and	 augmentation	materials	 (bone	 substitutes	
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(loss)	 needs	 to	 be	 investigated	 in	 randomized	 controlled	 clinical	
trials.
•	 The	 impact	of	compliance	with	supportive	care	 in	patients	with	
implants	placed	in	augmented	sites	on	the	development	of	long‐
term	biological	complications	and	 implant	 failure	 (loss)	needs	to	
be	 investigated	 in	well‐designed	observational	 studies	 and	 ran‐
domized	controlled	clinical	trials.
4  | OUTCOMES OF PERI‐ IMPL ANTITIS 




management	 of	 peri‐implantitis	 to	 achieve	 stable	 long‐term	 out‐
comes.	 The	 5th	 ITI	 Consensus	 found	 successful	 12‐month	 out‐
comes	 following	 peri‐implantitis	 treatment	 could	 be	 achieved	 in	





ported.	The	majority	of	 studies	 reported	 treatment	outcomes	 in‐
consistently.	Few	studies	reported	medium	to	long‐term	outcomes.	
Furthermore,	 the	 effect	 of	 supportive	 care	 (supportive	 peri‐im‐
plant/periodontal	 therapy,	 SPT)	 on	 treatment	 outcomes	was	 not	
addressed.
Therefore,	 the	 aim	 of	 this	 systematic	 review	was	 to	 evaluate	
the	 clinical	 outcomes	 for	patients	with	 implants	 treated	 for	peri‐
implantitis	who	subsequently	received	supportive	care	for	at	least	
3 years.
The	 primary	 outcome	 was	 survival	 (both	 at	 implant	 and	 pa‐
tient	 level),	 defined	 as	 the	 presence	 of	 the	 implant,	 regardless	 of	
the	 health	 of	 the	 surrounding	 tissues.	 Secondary	 outcomes	were	
























Although	 limited,	 there	 is	 evidence	 that	 implant	 surface	 can	 affect	
the	 medium‐	 to	 long‐term	 stability	 of	 peri‐implantitis	 treatment	
outcomes.
This	statement	is	based	on	the	findings	of	two	studies.	One	study	
found	 reduced	 success	 outcomes	 of	 implants	 with	 TPS	 (titanium	





Despite	 receiving	 regular	 supportive	 care,	 certain	 patients	 may	





4.3.1 | What definition of peri‐implantitis treatment 







In	addition,	patients	may	also	 require	 that	 their	 implant	 recon‐
structions	are	aesthetic,	comfortable,	and	easy	to	clean	in	order	to	
consider	the	treatment	a	success.
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4.3.3 | What peri‐implantitis treatment protocols could 




1. Thorough	 assessment	 and	 diagnosis.
2. Control	 of	 modifiable	 local	 and	 systemic	 risk	 factors	 for	
peri‐implantitis.
3. Nonsurgical	debridement.










4.3.4 | What supportive care protocols can be 









4.3.5 | Are there any implant variables that 
could influence long‐term outcomes of an implant 
successfully treated for peri‐implantitis?
Clinicians	 should	 be	 aware	 that	 implant	 surface	 characteristics	
may	 have	 an	 impact	 on	 treatment	 success.	 Other	 implant	 and	
prosthetic	variables	may	also	impact	on	treatment	success,	requiring	
modification	of	the	supportive	care	program.
4.4 | Recommendations for future research











thesis‐related	 factors	 on	 the	 long‐term	 outcomes	 of	 patients	
in	 supportive	 care	 following	 peri‐implantitis	 treatment	 are	
required.





5  | EFFEC T OF ADVANCED AGE , AND/
OR SYSTEMIC MEDIC AL CONDITIONS ON 
DENTAL IMPL ANT SURVIVAL
5.1 | Preamble
Today’s	 aged	 generation	 presents	 new	 challenges	 in	 the	 field	 of	
implant	dentistry.	Implant	patients	of	advanced	age	often	present	with	
functional	 dependency,	 systemic	medical	 conditions	 (comorbidities),	
and	 frailty.	 In	 addition,	 the	 aging	 of	 the	 immune	 system,	 termed	
immunosenescence,	may	 result	 in	a	compromised	host	defense	 to	a	














The	 systematic	 review	 included	 evidence	 from	60	 studies,	 of	
which	7	provided	sufficient	information	to	perform	meta‐analyses	
based	 on	 the	 primary	 outcome	 ‐	 implant	 survival	 in	 geriatric	 pa‐
tients	 (≥75	years).	One‐year	 implant	survival	was	based	on	7	pro‐
spective	 studies	with	 a	mean	of	 35	 implants,	 and	5‐year	 implant	
survival	 was	 based	 on	 3	 prospective	 studies	 with	 a	 mean	 of	 25	
implants.


















recall	 period	of	up	 to	5	years	 and	0.51	mm	 for	 the	 first‐year	 after	
loading.
5.2.3 | Consensus statement 3





































Patients	with	conditions	 involving	neurocognitive	 impairment	 (uni‐






No	 evidence	 was	 identified	 related	 to	 other	 diseases	 that	 are	
common	among	 the	elderly	 (WHO,	2015)	 such	as	 liver	 cirrhosis,	
respiratory	 diseases	 and	 osteoarthritis,	 in	 relation	 to	 implant	
therapy.
5.3 | Clinical recommendations





5.3.2 | Which common comorbidities comprise 
contraindications for implant placement?
High‐dose	 antiresorptive	 therapy	 (ART)	 poses	 a	 serious	 risk	 for	
postoperative	 complications	 and	 is	 a	 contraindication	 for	 implant	
surgery.	 If	 treated	 at	 all,	 these	 patients	 should	 be	 managed	 in	 a	
specialist	setting.
5.3.3 | Which common comorbidities comprise risks 
for implant placement?
Comorbidities	 such	 as	 cancer,	 diabetes	 mellitus,	 and	 conditions	
involving	 neurocognitive	 impairment	 may	 carry	 risks	 for	 implant	
therapy.	 An	 individual	 risk	 assessment	 is	 necessary	 before	
considering	 implant	 surgery	 for	 these	 patients.	 Implant	 patients	
with	comorbidities	should	be	managed	in	close	collaboration	with	a	
supervising	physician	with	regular	follow‐up.




5.3.4 | Which information must be taken into 
account when planning implant therapy for geriatric 
patients with common systemic diseases?
While	there	is	no	evidence	to	preclude	geriatric	patients	(≥75	years)	
from	 implant	 therapy	 it	 is	 advisable	 to	 perform	 an	 individual	 risk	
assessment	 for	 patients	 with	 comorbidities.	 In	 geriatric	 patients,	
a	 holistic	 approach	 is	 required	 which	 should	 include	 assessment	
of	 functional	dependency	 in	addition	 to	 related	 limitations	 for	 the	
use	of	implant‐supported	prostheses	and	the	ability	to	perform	oral	
hygiene	 measures.	 The	 progression	 of	 existing	 systemic	 disease	
and	dependency	as	well	as	the	patient’s	 life	expectancy	should	be	
considered	in	the	context	of	availability	of	competent	care.
5.3.5 | What are the risks and benefits associated with 
implant therapy in geriatric patients and patients suffering 





5.3.6 | What public health issues are important to 
consider for successful implant therapy in geriatric 
patients?
When	older	patients	lose	independence,	the	availability	of	trained	manpower	
in	 the	caring	professions	 is	a	potential	 limiting	 factor	 for	 implant	 therapy.	
Opportunities	for	education	and	additional	training	focused	on	oral	health	
should	be	provided	for	those	involved	in	caring	for	dependent	persons.





•	 Studies	 to	 address	 predictors	 for	 successful	 implant	 therapy	 in	
geriatric	patients	during	patient	selection,	prior	 to	 implant	 ther‐
apy	are	required.
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